Related Experiment Video
Updated: Oct 9, 2026
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
Upper Gastrointestinal Toxicity Associated With Long-Term Aspirin Therapy: Consequences and Prevention
Insights
Low-dose aspirin prevents cardiovascular events but causes gastrointestinal issues. A combination tablet with a proton pump inhibitor (PPI) may improve adherence and reduce risks, warranting further study.
Area of Science:
- Cardiology
- Gastroenterology
- Pharmacology
Background:
- Antiplatelet therapy, primarily low-dose aspirin, is crucial for secondary cardiovascular disease (CVD) prevention.
- Aspirin use carries a significant risk of gastrointestinal (GI) toxicity, including dyspeptic symptoms and ulceration, potentially leading to therapy discontinuation and increased CVD risk.
- Concomitant proton pump inhibitor (PPI) therapy is recommended for high-risk patients but faces challenges with under-prescribing and noncompliance.
Purpose of the Study:
- To evaluate the efficacy of a coordinated-delivery combination tablet of aspirin and a proton pump inhibitor (PPI).
- To assess the potential of this combination strategy to reduce upper GI toxicity and improve patient adherence to antiplatelet therapy.
- To advocate for further investigation of this approach in both controlled and real-world settings.
Main Methods:
- The study abstract discusses findings related to a combination tablet of aspirin and an immediate-release PPI.
- Evidence suggests this combination reduces gastric ulcer formation and improves patient compliance.
- Further research is proposed using randomized controlled (explanatory) and real-life (pragmatic) trials.
Main Results:
- A combination tablet of aspirin and a proton pump inhibitor (PPI) has demonstrated efficacy in reducing gastric ulcer formation.
- This integrated approach has shown potential for improving patient compliance with essential antiplatelet therapy.
- Reduced GI symptoms and enhanced adherence may ultimately lower cardiovascular outcomes.
Conclusions:
- Coordinated delivery of aspirin and a PPI in a single tablet offers a promising strategy to mitigate GI toxicity.
- Improved patient adherence due to reduced GI side effects could enhance the long-term effectiveness of aspirin therapy for CVD prevention.
- Further randomized and pragmatic trials are warranted to fully establish the clinical utility and impact of this combination therapy.
Abstract:
Antiplatelet therapy represents a fundamental part of preventive management for patients who are at risk of a secondary cardiovascular disease (CVD) event. In most cases, the antiplatelet regimen is based on low-dose aspirin, a drug that is highly effective in reducing the incidence of CVD events, but is associated with a substantial risk of gastrointestinal (GI) toxicity. The dyspeptic symptoms, which can result from aspirin administration, and which may occur with or without associated ulceration and bleeding, may lead patients to discontinue therapy, thus increasing their CVD risk. For patients in whom aspirin is indicated and who are deemed to be at increased risk of upper GI events, concomitant therapy with a proton pump inhibitor (PPI) is currently recommended. These agents are highly effective in reducing the upper GI lesions associated with aspirin therapy and have been associated with increased aspirin adherence. However, widespread under-prescribing of PPIs and potential noncompliance with their use means that substantial numbers of patients are at unnecessary risk of upper GI toxicity and-if aspirin therapy is discontinued-CVD events. Provision of aspirin and an immediate-release PPI as a coordinated-delivery combination tablet has been shown to both reduce the risk of gastric ulcer formation and improve patient compliance. This strategy, which may ultimately reduce the incidence of CVD outcomes because of the associated reduction in GI symptoms and the potential for greater patient adherence to aspirin, warrants further investigation under both randomized controlled conditions (explanatory trials), and in real-life settings (pragmatic trials).
Related Concept Videos
01:23Gastritis III: Clinical Manifestations and Management
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
01:28Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
01:30Drug toxicity: Drug–Drug Interaction
01:24Peptic Ulcer Disease II: Pathophysiology
01:25Peptic Ulcer Disease III: Clinical Manifestations and Complications